Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
about
Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generationOverview and recent advances in the treatment of neuroblastoma.Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells.Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Neuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group.Ultra-High Density SNParray in Neuroblastoma Molecular DiagnosticsSurgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model.A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastomaTreatment results and prognostic factors of pediatric neuroblastoma: a retrospective studyChemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.Genomic medicine and neuroblastoma.Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells.Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology GroupOutcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell linesMYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.Experience with International Neuroblastoma Staging System and Pathology Classification.Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma.Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma.International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteePresence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsIs complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?Prenatal diagnosis of adrenal neuroblastoma: a case report with a brief review of the literature.Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts.Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review.Nuclear condensation and cell cycle arrest induced by telomerase siRNA in neuroblastoma cells.Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma.Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.Successful treatment of infants with localized neuroblastoma based on their MYCN status.Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
P2860
Q28477973-095B91D9-14E5-4778-9641-580D3E411275Q30238693-281EBEFB-7D60-47B0-8AE6-28D4F8E43285Q33516119-25447063-EA99-4799-8D15-63220FD64B22Q33834340-4986628D-39E4-4516-A76D-48CC44A0F973Q33872797-FDFDAAFD-B829-4286-A996-F59D1419F30CQ34032495-526FF825-CAE0-4F1E-BA8F-2962A370D8DFQ34051924-1F14DFAD-9D6B-4865-BC9C-8551DB1FE7FBQ34278642-02AB7B31-88EB-4C1C-BBCF-6368453D3876Q34477899-11DF9DE0-5DE9-4E5F-B5D9-C97C5827377CQ34505680-842457D8-0702-4E8F-AC9A-4623DA9CA9D4Q34543549-2ED2C69D-181F-4C51-9463-F83B07B4D16DQ34703990-9338DBB5-01C3-4D62-A40B-54E6650FCF4BQ34891827-4F62D1E7-8FC5-4442-BA46-203A61F19B51Q35045279-2C9992FB-2046-40DA-B928-54C419881981Q35248327-56AAC1BB-7213-4C53-AE5B-6CA5AFD93F5CQ36010031-BD2FF00D-7E52-4FC8-9586-DA8CAF92764FQ36058508-073CF11F-8194-4070-88B5-DCABF351F0CCQ36096809-FB703E50-5CAC-4885-8C0D-F0C8F3B1257AQ36168388-081825CD-F1DA-4913-89C1-E2224182052AQ36614178-91C63FDB-3183-49DA-B317-564A1EC50CBFQ36614690-F17F10FB-54A8-42BB-BA0D-D478675F34FDQ36623808-029D0662-6891-455C-BC1C-224E61195A79Q36845731-9220172A-C758-4576-92B7-1835B3DE4581Q36936057-E3D9D0F9-BE22-42EE-89D1-B3AFE161849DQ37035532-2DBF6B13-DFD9-4895-927B-2EF89A3314A8Q37188218-2540BAFC-9F87-4AF1-95AB-DB7C1FAB11BCQ37222603-FD19C82C-4415-4DD4-9703-F73623E80366Q37284320-41BBF60D-155D-48CE-B17F-9C79C9C9E66DQ37316127-537ABB3E-3FAD-4CCF-B8FD-1243B1C4C457Q37461968-D09036ED-4F58-4DD3-8DDF-4CD04ED4A736Q38020759-B6A975C5-1DAB-4E6E-9F47-B9DD195FDBA5Q38100793-8821368D-A177-4382-B120-D984B347A9B4Q38770676-0A7E786B-E728-4B09-AFC2-94EAEFC06457Q39114900-039479F5-10F6-4566-9FA7-2C334C874EC7Q39226403-D184B5F6-D58D-4BD6-8865-EF9E13E002D9Q39362601-C17A4D18-35FF-4390-890D-C324DE09A367Q43169185-DD29641A-730E-4894-AE7E-1838D32F06B3Q43170089-1CA24F15-DFA7-400A-999F-B97264383E44Q44324167-70721F7D-3A1A-4699-A37C-035C314A9902Q46464273-A50152F4-D036-4F7D-B54F-50FBC846E3FD
P2860
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Biologic variables in the outc ...... children's cancer group study.
@en
type
label
Biologic variables in the outc ...... children's cancer group study.
@en
altLabel
Biologic variables in the outc ...... children's cancer group study
@en
prefLabel
Biologic variables in the outc ...... children's cancer group study.
@en
P2093
P356
P1476
Biologic variables in the outc ...... children's cancer group study.
@en
P2093
J B Atkinson
J N Lukens
K K Matthay
R B Gerbing
R C Seeger
P356
10.1200/JCO.2000.18.1.18
P407
P577
2000-01-01T00:00:00Z